Biohaven Therapeutics Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO40%
Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Biohaven Therapeutics Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Taldefgrobep Alfa NCT07281495 |
P2 | Active, not recruiting | Obesity; Overweight | 150 | 2026-09 |
| RISE 3 NCT06309966 |
P2/3 | Active, not recruiting | Focal Epilepsy | 390 | 2026-10 (+14 mo) |
| BHV-7000 NCT06443463 |
P2 | Enrolling by invitation | Focal Epilepsy | 660 | 2026-12 |
| RISE 2 NCT06132893 |
P2/3 | Active, not recruiting | Focal Epilepsy | 390 | 2026-12 (+16 mo) |
| BHV-8000 10mg NCT06976268 |
P2/3 | Recruiting | Parkinson Disease | 550 | 2027-08 |
| BHV-1300 NCT07661056 |
P3 | Recruiting | Graves Disease | 300 | 2028-01 |
| BHV-1510 NCT06384807 |
P1/2 | Recruiting | Solid Tumor | 500 | 2028-02 |
| BHV-1400 NCT07642050 |
P3 | Not yet recruiting | IgA Nephropathy | 420 | 2028-09 |
| BHV-1300 NCT07901244 |
P2/3 | Not yet recruiting | Graves' Disease | 356 | 2028-12 |